Medicare Enrolled
Dr. Norman Gebrosky, MD
Urology Physician · Latrobe, PA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Gebrosky from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Gebrosky?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Gebrosky
Dr. Norman Gebrosky is an urology physician in Latrobe, PA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Gebrosky performed 3,994 Medicare services across 1,962 unique beneficiaries.
Between the years covered by Open Payments, Dr. Gebrosky received a total of $6,673 from 52 pharmaceutical and/or device companies across 336 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in urology physician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Gebrosky is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 14% volume in PA
$6,673 industry payments
Medicare Practice Summary
Medicare Utilization ↗3,994
Medicare services
Top 14% in PA for urology physician
1,962
Unique beneficiaries
$57
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~210 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Leuprolide injectable, camcevi, 1 mg | 966 | $67 | $120 |
| Infectious disease DNA/RNA test A laboratory test that uses a specific technique to detect the genetic material of an organism. This method amplifies the target DNA or RNA to identify the presence of the organism. |
442 | $34 | $75 |
| Urinalysis, manual A manual laboratory examination of a urine sample to check for various substances and cells. |
438 | $3 | $12 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
408 | $87 | $155 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
375 | $57 | $110 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
219 | $62 | $115 |
| Yeast/candida DNA test A laboratory test that uses an amplified probe technique to detect the presence of Candida species, a type of yeast, in a patient sample. |
170 | $34 | $75 |
| Manual urinalysis with microscopic examination A urine test performed manually without automated equipment. The sample is examined under a microscope to check for abnormalities. |
130 | $4 | $12 |
| Bladder ultrasound after voiding An ultrasound scan performed after urination to measure the amount of urine remaining in the bladder. |
117 | $7 | $150 |
| Nucleic acid test for multiple organisms A laboratory test that uses amplified probe techniques to detect the genetic material of multiple organisms in a sample. |
102 | $69 | $175 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
79 | $135 | $280 |
| Cystourethroscopy A diagnostic exam of the bladder and urethra using an endoscope to visually inspect the urinary tract. |
68 | $176 | $385 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
65 | $120 | $225 |
| Bladder instillation of anti-cancer drug A procedure where an anti-cancer medication is introduced directly into the bladder. This method delivers the treatment locally to the bladder tissue. |
56 | $62 | $218 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
37 | $66 | $175 |
| VRE nucleic acid detection test A laboratory test that uses amplified probe techniques to detect vancomycin-resistant Enterococcus (VRE) DNA in a patient sample. |
34 | $34 | $75 |
| Staphylococcus aureus DNA test A laboratory test that uses DNA amplification to detect the presence of Staphylococcus aureus bacteria in a sample. |
34 | $34 | $75 |
| MRSA nucleic acid detection test A laboratory test that uses amplified probe techniques to detect the genetic material of methicillin-resistant Staphylococcus aureus (MRSA) bacteria. |
34 | $34 | $75 |
| Strep A nucleic acid amplification test A laboratory test that uses nucleic acid amplification to detect the presence of Group A Streptococcus bacteria. This method identifies the genetic material of the bacteria to determine if an infection is present. |
34 | $34 | $75 |
| Group B Strep DNA test A laboratory test that uses DNA amplification to detect the presence of Group B Streptococcus bacteria. |
34 | $34 | $75 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
33 | $24 | $80 |
| Transrectal ultrasound of the pelvis An ultrasound imaging procedure where a probe is inserted into the rectum to visualize pelvic structures. |
30 | $105 | $400 |
| Prostate gland biopsy A procedure to remove small samples of tissue from the prostate gland for laboratory examination. |
25 | $177 | $400 |
| Simple insertion of temporary bladder tube A procedure to place a temporary tube into the bladder. This allows for the drainage of urine from the bladder. |
23 | $45 | $112 |
| Ureteral stent insertion via endoscope A flexible tube is inserted into the ureter using an endoscope to keep the passage open and allow urine to flow from the kidney to the bladder. |
14 | $107 | $780 |
| Ureteral stone crushing with stent insertion An endoscope is used to break up a stone in the ureter, followed by the placement of a stent to keep the ureter open. |
14 | $321 | $900 |
| Shock wave crushing of kidney stones A procedure that uses shock waves to break kidney stones into smaller pieces so they can pass more easily from the body. |
13 | $445 | $2,000 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
0.7% high complexity
5.1% medium
94.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$6,673
Total received (2018-2024)
Avg $953/year across 7 years
Top 21% in PA for urology physician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
52
Companies
336
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$6,451 (96.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$221 (3.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$738
2023
$823
2022
$1,227
2021
$968
2020
$1,537
2019
$495
2018
$885
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Sumitomo Pharma America, Inc.
$261
Astellas Pharma US Inc
$108
Janssen Biotech, Inc.
$73
Myriad Genetic Laboratories, Inc.
$67
Antares Pharma, Inc.
$32
PROCEPT BioRobotics Corporation
$31
AstraZeneca Pharmaceuticals LP
$31
UROGEN PHARMA, INC.
$27
Merck Sharp & Dohme LLC
$22
Cumberland Pharmaceuticals, Inc.
$20
Bayer Healthcare Pharmaceuticals Inc.
$19
Tolmar, Inc.
$17
Ferring Pharmaceuticals Inc.
$15
PFIZER INC.
$14
Top 3 companies account for 59.9% of 2024 payments
All-time payments by company (2018-2024) ›
Astellas Pharma US Inc
$1,085
Boston Scientific Corporation
$978
Janssen Biotech, Inc.
$714
PFIZER INC.
$493
Sumitomo Pharma America, Inc.
$408
Myovant Sciences Inc.
$324
Blue Earth Diagnostics Limited
$305
Myriad Genetic Laboratories, Inc.
$297
AstraZeneca Pharmaceuticals LP
$199
Cumberland Pharmaceuticals, Inc.
$142
UROVANT SCIENCES INC
$135
TOLMAR Pharmaceuticals, Inc.
$121
Antares Pharma, Inc.
$113
Merck Sharp & Dohme LLC
$90
MEDIVATION FIELD SOLUTIONS LLC
$90
Dendreon Pharmaceuticals LLC
$84
BOSTON SCIENTIFIC CORPORATION
$79
Merck Sharp & Dohme Corporation
$76
AbbVie, Inc.
$67
Progenics Pharmaceuticals, Inc.
$63
Avadel Specialty Pharmaceuticals, LLC
$56
Bayer HealthCare Pharmaceuticals Inc.
$51
Bayer Healthcare Pharmaceuticals Inc.
$46
Ferring Pharmaceuticals Inc.
$42
UROGEN PHARMA, INC.
$40
UroGen Pharma, Inc.
$37
Coloplast Corp
$34
DENTSPLY IH Inc.
$34
PROCEPT BioRobotics Corporation
$31
SI-BONE, Inc.
$31
Axonics, Inc.
$27
Supernus Pharmaceuticals, Inc.
$25
Sun Pharmaceutical Industries Inc.
$23
Aytu BioScience, Inc
$23
Alexion Pharmaceuticals, Inc.
$22
Travere Therapeutics, Inc.
$21
Accord Healthcare, Inc.
$21
Allergan, Inc.
$21
Mission Pharmacal Company
$20
C. R. Bard, Inc. & Subsidiaries
$19
Foundation Medicine, Inc.
$18
C. R. BARD, INC. & SUBSIDIARIES
$18
Retrophin, Inc.
$17
Covidien LP
$17
Verity Pharmaceuticals Inc.
$17
Tolmar, Inc.
$17
Metuchen Pharmaceuticals
$15
Amgen Inc.
$14
Olympus America Inc.
$14
Celgene Corporation
$13
Cook Medical LLC
$12
Axonics Modulation Technologies, Inc.
$12
Top 3 companies account for 41.6% of all-time payments
Associated products mentioned in payments ›
(815) Thiola · ADSTILADRIN · AQUABEAM SYSTEM · Androgel · Axonics · Axonics r-SNM System · Axumin · BOTOX · Bard SkyLite Tipless Nitinol Stone Basket · CALDOLOR · CAMCEVI · COOK MEDICAL WIRE GUIDES · Caldolor · ELIGARD · ERLEADA · Erleada · GEMTESA · GENERAL BPH · JELMYTO · KEYTRUDA · LYNPARZA · LYRICA · LoFric · Lupron · MYRBETRIQ · Myrbetriq · NOCDURNA · Natesto · Noctiva · Nubeqa · OPDIVO · ORGOVYX · OTREXUP · PREMARIN · PROLARIS · PROVENGE · PYLARIFY · Prolaris · SPACEOAR · SPEEDICATH · Stendra · TLANDO · TOVIAZ · Thiola · Trelstar · Uribel · XGEVA · XTANDI · XYOSTED · Xofigo · Xtandi · YONSA · iTIND System
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (97%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Urology physicians within 10 mi
18
Per 100K population
5.1
County median income
$72,468
Nearest hospital
EXCELA HEALTH LATROBE HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Gebrosky is a clinical cardiology specialist, with above-average Medicare volume (top 14% in PA), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Gebrosky experienced with leuprolide injectable, camcevi, 1 mg?
Based on Medicare claims data, Dr. Gebrosky performed 966 leuprolide injectable, camcevi, 1 mg services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Gebrosky receive payments from pharmaceutical companies?
Yes. Dr. Gebrosky received a total of $6,673 from 52 companies across 336 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Gebrosky's costs compare to other urology physicians in Latrobe?
Dr. Gebrosky's average Medicare payment per service is $57. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Gebrosky) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Urology Physicians in Latrobe
Browse urology physicians in Latrobe ranked by procedure volume and transparency data.
Highest volume
Top Urology Physicians in PA
Urology physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Urology Physicians in PA
Which PA urology physicians receive the most from drug and device companies.
By company
Astellas Pharma US Inc Payments to Doctors
See all physicians who received payments from Astellas Pharma US Inc.
By company
Boston Scientific Corporation Payments to Doctors
See all physicians who received payments from Boston Scientific Corporation.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology